Back to Journals » Infection and Drug Resistance » Volume 13

Eight-Year Surveillance of Uropathogenic Escherichia coli in Southwest China

Authors Sun J, Du L, Yan L, Dai W, Wang Z, Xu X

Received 21 February 2020

Accepted for publication 7 April 2020

Published 28 April 2020 Volume 2020:13 Pages 1197—1202

DOI https://doi.org/10.2147/IDR.S250775

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony


Jide Sun,1 Li Du,2 Li Yan,1 Wei Dai,1 Zhu Wang,1 Xiuyu Xu1

1Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2College of Basic Science, Chongqing Medical University, Chongqing, People’s Republic of China

Correspondence: Li Yan Tel +86 23 89012742
Fax +86 23 89012513
Email cqyanli2000@126.com

Purpose: To assess antimicrobial resistance profiles change in uropathogenic Escherichia coli (UPEC) during an 8-year period, especially extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant isolates.
Materials and Methods: A retrospective observational study of urinary tract infections (UTIs) was performed in a territory hospital between 2012 and 2019. Isolates were identified using matrix-assisted laser desorption/ionization time of flight mass spectrometry or the VITEK 2 Compact system. The antimicrobial susceptibility testing was performed using the VITEK 2 Compact system and the modified Kirby–Bauer disc diffusion method.
Results: Of the  7713 non-repetitive UPEC isolates, 7075 (91.7%) were from inpatients and 638 (8.3%) were from outpatients. The prevalence of ESBL declined from 62.5% to 49.7% (P =  0.003). Except for cefoxitin, the resistance rates of ESBL-producing isolates were mostly higher than that of non-ESBL-producing isolates (P <  0.001). The resistance rates of ampicillin (P =  0.013), ampicillin/sulbactam (P =  0.013), ceftriaxone (P <  0.001), gentamycin (P =  0.001), tobramycin (P =  0.011), and trimethoprim/sulfamethoxazole (P =  0.028) declined slightly, while the resistance rate of imipenem increased slightly (P =  0.001). The prevalence of carbapenem-resistant Escherichia coli was < 2.0%.
Conclusion: ESBL-producing Escherichia coli is still the main drug-resistant bacteria causing UTIs. We should pay attention to antimicrobial resistance in high-risk inpatient areas and take effective measures to prevent and control nosocomial infections.

Keywords: UTIs, ESBL, E. coli, CRE, antimicrobial resistance, trends

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]